Surgical Outcomes in Splenic Flexure Cancers: A Multicenter Comparison of Segmental vs. Extended Hemicolectomy (SPARROW Study)
Cancers at the splenic flexure of the colon are rare, and surgeons disagree on how much bowel to remove. This multicenter study compares outcomes of limited (segmental) versus extended colon resections.
Surgical Outcomes in Splenic Flexure Cancers: A Prospective, Multicentric Observational Cohort Study Comparing Segmental Hemicolectomy and Extended Hemicolectomy - The SPARROW Study
SPARROW Study: Surgical Outcomes in Splenic Flexure Cancer
Colonic cancers located at the splenic flexure where the transverse colon turns into the descending colon are uncommon and represent less than 10% of all colorectal cancers. Because of their unique location between the blood supply of the right and left colon, there is no clear agreement on which surgical method provides the best results.
Two main procedures are used:
Segmental hemicolectomy, which removes only the part of the colon containing the tumor, and
Extended hemicolectomy, which removes a larger section of the colon and more lymph nodes.
The SPARROW Study is a prospective, multicenter observational study designed to compare these two surgical approaches in patients with splenic flexure cancer. The study will include about 140 patients (70 in each group) from multiple tertiary colorectal centers in Turkey and Europe.
Researchers will collect information about each patient's surgery, recovery, and follow-up outcomes. The main outcomes include postoperative ileus, leakage at the surgical connection (anastomosis), wound infection, and total postoperative complications. Other outcomes include number of lymph nodes removed, complete tumor resection (R0), hospital stay, recovery time, reoperation, and 3-year overall and disease-free survival.
By analyzing both short- and long-term results, the SPARROW Study aims to provide high-quality evidence to guide surgeons in choosing the best and safest operation for patients with splenic flexure cancers.
All participants will provide written informed consent before joining the study. The study has received ethical approval from the Koç University Ethics Committee and will be conducted in accordance with the Declaration of Helsinki.
+Read the detailed description
Study Rationale:
Splenic flexure cancers pose unique surgical challenges due to their variable blood supply and lymphatic drainage. The optimal extent of resection remains controversial, with both extended right and left colectomy approaches showing different technical advantages. However, there are no prospective multicenter data comparing their perioperative and oncologic outcomes.
Study Design:
This is a prospective, multicenter observational cohort study involving tertiary colorectal cancer centers. The study will enroll 140 consecutive adult patients (≥18 years old) undergoing elective curative resection for histologically confirmed splenic flexure adenocarcinoma. Surgical approach-segmental or extended colectomy-will be chosen according to the operating surgeon's routine practice and preference, not assigned by randomization.
Primary Outcomes:
Postoperative ileus (incidence and duration)
Anastomotic leakage
Wound infection
Total postoperative complications
Secondary Outcomes:
Lymph node yield and R0 resection rate
Postoperative mortality
Operation time and estimated blood loss
Hospital stay, return to regular diet, and time to first flatus
Reoperation rates
3-year overall survival (OS) and disease-free survival (DFS)
Timeline:
Study start: 2025
Enrollment period: 24 months
Follow-up: 36 months per patient
Total duration: approximately 5 years
Ethical Conduct:
Ethical approval was obtained from the Koç University Ethics Committee. Each participat...
- Colon Cancer
- Splenic Flexure Mobilization
- Right Hemicolectomy
- Left Hemicolectomy
- Segmental Colectomy
- Extended Hemicolectomy
- Colectomy
- Incidence of Postoperative Ileus After Surgery for Splenic Flexure Cancer — Within 30 days after surgery
Criteria are written for physicians. Do not rule yourself out: send your reports and the study team will check.
- Acıbadem, Istanbul
Source: ClinicalTrials.gov NCT07289568 · last updated 2025-12-17 · View registry record ↗